MedTech Business - March 16, 2022
CardiNor announces CE marking and launch of new risk marker
CardiNor has announced that it has achieved CE marking according to IVDD for the CardiNor Secretoneurin ELISA test. This new frontline biomarker for cardiovascular disease reflects the biological mechanism triggering arrhythmia. CardiNor has a clinical program to further strengthen and widening the clinical documentation of its novel biomarker, and the CardiNor Secretoneurin (SN) test is […]
Financing - April 27, 2021
CardiNor secures NOK 12 million
CardiNor has secured NOK 12 million to commercialize the development of an ELISA test for secretoneurin (SN), a potentially new innovative biomarker for cardiovascular disease. The company will use the funds for CE marking, initiate US regulatory activities and expanding the range of indications, it states in a press release. In addition to existing investors, […]
Acquisition - January 14, 2016
Bioventix invests in CardiNor
The cardiovascular diagnostics start-up CardiNor AS has entered a collaboration with the UK antibody specialist Bioventix plc. Under the terms of the agreement Bioventix will develop and provide antibodies for CardiNor’s new Secretoneurin (SN) IVD test. Aimed at the estimated USD 4 billion cardiovascular risk assessment market, the assay is intended for launch in early 2017. Under the […]
Acquisition - November 10, 2015
CardiNor receives USD 0,75M
CardiNor AS, a newly established Norwegian biotech company has received an initial USD 0,75 million to start development of an IVD for the neuropeptide Secretoneurin (SN). This neuropeptide is creating a great deal of interest as the potential missing link in assessment and management of the 30 million patients having arrythmia. The new company’s management, […]
